Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Sep 2026
Technique deemed safe and feasible for selected patients and better than other minimally invasive approaches
Read Full News1.
Since 2000, the outlook for multiple myeloma has improved.
2.
Risk of a second cancer after early breast cancer is low, say new findings
3.
unhealthy sleeping habits and the risk of esophageal adenocarcinoma.
4.
Body Clock Genes Tied to Prostate Radiotherapy Toxicity
5.
Trial Questions Role of Dual Immunotherapy in First-Line NSCLC
1.
Understanding Phyllodes Tumor: Symptoms, Diagnosis, and Treatment Options
2.
Unveiling Canine Blood Clots Over Time: A Look at Low-Field MRI's Diagnostic Potential
3.
Immunotherapy Tolerance in Older Adults With Cancer
4.
Unlocking the Key to Treating Lymphoma: New Innovations in Cancer Research
5.
Cardio-Oncology in Survivors: Safeguarding Hearts Through Multidisciplinary Care
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
2.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
4.
Recognizing Symptoms That May Require Cancer Evaluation
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge